Skip to main content

Market Overview

Recap: IDEXX Laboratories Q4 Earnings



Shares of IDEXX Laboratories (NASDAQ:IDXX) were unchanged after the company reported Q4 results.

Quarterly Results

Earnings per share were up 69.23% year over year to $1.76, which beat the estimate of $1.40.

Revenue of $720,938,000 rose by 19.08% from the same period last year, which beat the estimate of $681,020,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $7.39 and $7.71.

The upcoming fiscal year's revenue expected to be between $3,065,000,000 and $3,120,000,000.

How To Listen To The Conference Call

Date: Feb 02, 2021

Time: 08:30 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $516.87

Company's 52-week low was at $168.65

Price action over last quarter: Up 15.91%

Company Overview

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 38% of its revenue from outside the United States.


Related Articles (IDXX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at